• PNS11 FUNDING OF MANAGEMENT AND INCORPORATION OF TECHNOLOGIES IN BRAZILIAN HEALTH SYSTEM

    Oct 1, 2019, 00:00

  • PDG6 EVALUACION ECONOMICA DE DEXAMETASONA IMPLANTE PARA EL TRATAMIENTO DE PACIENTES CON EDEMA MACULAR DIABETICO

    Oct 1, 2019, 00:00

  • PND13 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PCN36 EXPERIENCIAS EN LA IMPLEMENTACIÓN DE METODOLOGÍAS O CRITERIOS PARA DETERMINAR EL VALOR TERAPÉUTICO DE MEDICAMENTOS ONCOLÓGICOS: UNA REVISIÓN RÁPIDA DE LA LITERATURA

    Oct 1, 2019, 00:00

  • PMS7 A STANDARD COSTING FOR MODERATE-SEVERE RHEUMATOID ARTHRITIS FROM THE COLOMBIAN HEALTH SYSTEM PERSPECTIVE

    Oct 1, 2019, 00:00

  • PCV9 IMPACTO CLINICO Y ECONOMICO DE LAS ENFERMEDADES CARDIOVASCULARES (ECV) EN LA POBLACION ADULTA DENTRO DEL SISTEMA DE SALUD DE MEXICO.

    Oct 1, 2019, 00:00

  • PCN17 COSTO-EFECTIVIDAD DE AFATINIB COMO PRIMERA LÍNEA EN EL TRATAMIENTO DEL CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS AVANZADO CON MUTACIÓN POSITIVA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO EN COLOMBIA

    Oct 1, 2019, 00:00

  • PNS46 ATENCION VIRTUAL EN SALUD: DE LA ESTRATEGIA A LA TACTICA

    Oct 1, 2019, 00:00

  • RE1 THE IMPACT OF REAL-WORLD EVIDENCE ON REIMBURSEMENT SUBMISSIONS: ARE WE CLEAR ON CURRENT PRACTICES?

    Oct 1, 2019, 00:00

  • TP3 Estudio de utilizacion de drogas: Descripción del uso de inmunoglobulina intravenosa humana en un Hospital Universitario de Bogotá, Colombia

    Oct 1, 2019, 00:00

  • PSY1 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA ECUATORIANA

    Oct 1, 2019, 00:00

  • PND11 ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS OTHER DISEASE MODYFING THERAPIES IN PUBLICLY INSURED BRAZILIAN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PRS7 ¿REALMENTE ES UNA AMENAZA PARA LA SALUD DE LOS COLOMBIANOS?

    Oct 1, 2019, 00:00

  • PNS39 HOW VALUE IS DEFINED BY DIFFERENT STAKEHOLDERS IN BRAZIL?

    Oct 1, 2019, 00:00

  • PSY11 ADESAO E CUSTOS ASSOCIADOS AO TRATAMENTO PROFILATICO DE PACIENTES HEMOFILICOS NO BRASIL

    Oct 1, 2019, 00:00

  • PMH2 THE ENVIRONMENT DISASTER OF BRAZILIAN MINING OF MARIANA IN THE HEALTH ECONOMIC CONTEXT: PSYCHOLOGICAL TRAGEDY COST

    Oct 1, 2019, 00:00

  • PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • PNS35 THE EFFECT OF FINANCIAL INCENTIVE ON RETAINING DENTISTS IN RURAL AREAS IN THAILAND

    Oct 1, 2019, 00:00

  • PCN62 PRELIMIANARY ANALYSIS OF TIROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA A FIVE YEARS FOLLOW-UP FROM A REAL WORLD COHORT

    Oct 1, 2019, 00:00

  • PDB1 CALIDAD DE VIDA ASOCIADA CON OBESIDAD EN PACIENTES MEXICANOS

    Oct 1, 2019, 00:00

  • PND5 COST-EFFECTIVENESS OF MECHANICAL THROMBECTOMY USING SOLITAIRE STENT RETRIEVER IN COMBINATION WITH INTRAVENOUS TISSUE PLASMINOGEN ACTIVATOR (IV-TPA) VERSUS IV-TPA ALONE FOR THE TREATMENT OF ACUTE ISCHAEMIC STROKE DUE TO LARGE VESSEL OCC ...

    Oct 1, 2019, 00:00

  • CV4 EVALUACION DE LOS MOTIVOS DE LA OMISION DE RETIROS DE MEDICAMENTOS PENDIENTES EN LA OFICINA DE FARMACIA. POSIBLES SOLUCIONES

    Oct 1, 2019, 00:00

  • PMS3 PSYCHOLOGY CONSULTATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS - A LOW-COST INTERVENTION WITH GREAT BENEFITS

    Oct 1, 2019, 00:00

  • TP4 REAL-WORLD PATIENT CHARACTERISTICS AND OUTCOMES OF RESECTED STAGE III MELANOMA PATIENTS IN ARGENTINA AND BRAZIL

    Oct 1, 2019, 00:00

  • EP2 PUBLIC HEALTH AND ECONOMIC IMPACT OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR

    Oct 1, 2019, 00:00

  • CN4 ANÁLISIS DE COSTO-UTILIDAD E IMPACTO PRESUPUESTARIO DE LA ENZALUTAMIDA PARA EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN NO METASTÁSICO (CPRCNM) EN ARGENTINA

    Oct 1, 2019, 00:00

  • PSU2 EFECTIVIDAD Y SEGURIDAD DEL USO DE LOS IMPLANTES DE AHMED, MOLTENO Y BAERVELDT EN PACIENTES OPERADOS CON GLAUCOMA CRONICO: UN META-ANALISIS EN RED

    Oct 1, 2019, 00:00

  • PMH8 EXPERIENCES AND HEALTH NEEDS OF ASYLUM SEEKERS AND REFUGEES OF LATIN AMERICAN ORIGIN IN CHILE

    Oct 1, 2019, 00:00

  • PMS19 MANAGEMENT AND COSTS OF THERAPY FOR OSTEOARTHRITIS

    Oct 1, 2019, 00:00

  • PMU1 POTENTIAL PRODUCTIVITY YEARS OF LIFE LOST RELATED TO DEATHS CAUSED BY RESIDENTIAL RADON AND BONE LEAD IN COLOMBIA, 2016

    Oct 1, 2019, 00:00

  • PND12 WORK PRODUCTIVITY AND DAILY ACTIVITIES IMPAIRMENT (WPAI) IN CHILEAN PATIENTS WITH MIGRAINE: PERSPECTIVES ON INDIRECT-COSTS DRIVERS

    Oct 1, 2019, 00:00

  • PCN44 DESIGUALDADES EN EL DIAGNÓSTICO DE CÁNCER DE CÉRVIX EN LAS REGIONES DE COLOMBIA

    Oct 1, 2019, 00:00

  • PUK7 ANALISIS DE EFECTIVIDAD Y SEGURIDAD DE MIRABEGRON EN PACIENTES CON SINDROME DE VEJIGA HIPERACTIVA

    Oct 1, 2019, 00:00

  • PMH10 TREATMENT-RESISTANT DEPRESSION IN LATIN AMERICA: PRELIMINARY RESULTS FROM THE TRAL STUDY

    Oct 1, 2019, 00:00

  • PMS8 CONVENTIONAL VERSUS BIOLOGICAL TREATMENT FOR ANKYLOSING SPONDYLITIS. RESULTS FROM A REAL-LIFE SETTING

    Oct 1, 2019, 00:00

  • PND4 ANALISIS DE MINIMIZACION DE COSTOS DE TOPIRAMATO DE LIBERACION PROLONGADA PARA LA PREVENCION DE MIGRAÑA EN ADULTOS Y ADOLESCENTES A PARTIR DE LOS 12 AÑOS

    Oct 1, 2019, 00:00

  • PIN4 A BUDGET IMPACTO ANALYSIS OF TENOFOVIR ALAFENAMIDE/EMTRICITABINE (DESCOVY®) FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PATIENTS AGED 12 YEARS AND OLDER, IN MEXICO

    Oct 1, 2019, 00:00

  • PIN26 PRINCIPALES ESQUEMAS ANTIRRETROVIRALES USADOS EN LAS PERSONAS QUE VIVEN CON EL VIH EN COLOMBIA. 2018

    Oct 1, 2019, 00:00

  • PNS15 DOES FOOD INSECURITY AFFECT PERFORMANCE AT SCHOOL? EVIDENCE FROM BRAZIL

    Oct 1, 2019, 00:00

  • PNS45 APPLYING A RAPID REVIEW METHODOLOGY TO INFORM THE UPDATE OF ARGENTINA'S HEALTH BENEFIT PACKAGE

    Oct 1, 2019, 00:00

  • PRO11 ANÁLISIS DE SERIE DE CASOS DE PACIENTES CON DIAGNÓSTICO DE HEMOFILIA A CON INHIBIDORES EN HOSPITALES DE ALTA COMPLEJIDAD EN ECUADOR

    Oct 1, 2019, 00:00

  • PCN24 COST-EFFECTIVENESS OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FOR PATIENTS WITH BRAF+ MUTATION FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2019, 00:00

  • PIN20 OVERVIEW OF MORTALITY DUE TO ANTIMICROBIAL RESISTANT INFECTIONS

    Oct 1, 2019, 00:00

  • PRO9 PUBLIC PURCHASES OF ECULIZUMABE BY THE BRAZILIAN MINISTRY OF HEALTH: A PROFILE OF VOLUMES AND EXPENSES FROM 2007 TO 2018

    Oct 1, 2019, 00:00

  • PNS3 BRAZILIAN PHARMACEUTICAL INDUSTRY: THE IMPACT OF PUBLIC POLICIES AIMED AT FOSTERING LOCAL MANUFACTURING

    Oct 1, 2019, 00:00

  • PDG10 DRUGS WITH DISCONTINUED PRODUCTION: A DESCRIPTIVE ANALYSIS OF THE BRAZILIAN SCENARIUM

    Oct 1, 2019, 00:00

  • PCN39 ACCESS TO MEDICAL INTERVENTIONS IN BRAZIL: THE ROLE OF CLINICAL RESEARCH AND OF HEALTH JUDICIALIZATION

    Oct 1, 2019, 00:00

  • PRO14 COMPARAR A INCIDÊNCIA DE COMORBIDADES NO TRATAMENTOS DE MIELOMA MÚLTIPLO ENTRE AS TERAPIAS DO SISTEMA DE SAÚDE BRASILEIRO (SUS) COM AS AINDA NÃO INCORPORADAS

    Oct 1, 2019, 00:00

  • PNS59 IMPACTO DEL MODELO DE RIESGO COMPARTIDO EN LA TASA DE EVENTOS HOSPITALARIOS DE UN SEGURO VOLUNTARIO EN COLOMBIA

    Oct 1, 2019, 00:00

  • PNS52 EQ-5D-5L SOCIAL VALUES IN PERU: A NOVEL "LITE” APPROACH

    Oct 1, 2019, 00:00

  • CM4 TIME TO TREATMENT EFFECT, EVENT-FREE SURVIVAL, AND MOTOR MILESTONE ACHIEVEMENT IN TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC (AVXS-101) OR NUSINERSEN CONTRASTED TO NATURAL HISTORY

    Oct 1, 2019, 00:00

  • PNS36 TRENDS IN UNITED STATES EMERGENCY DEAPARTMENT VISITS AND CHARGES, 2010-2016

    Oct 1, 2019, 00:00

  • PND1 COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE IN HIGH DISEASE ACTIVITY RELAPSE REMITTING MULTIPLE SCLEROSIS IN ARGENTINA

    Oct 1, 2019, 00:00

  • PNS18 HOW IS SELF-PERCEIVED HEALTH STATUS (EQ-5D) ASSOCIATED WITH PSYCHOSOCIAL FACTORS IN 22 LATIN AMERICAN COUNTRIES?

    Oct 1, 2019, 00:00

  • PNS48 USE OF REAL WORLD DATA FOR DEVELOPMENT OF AN ALGORITHM TO EVALUATE THE COMPLEXITY OF PEOPLE WITH CHRONIC DISEASES CONTROLLING FOR SOCIOECONOMIC AND ENVIRONMENTAL INEQUALITIES

    Oct 1, 2019, 00:00

  • PCN64 ANALISIS COMPARATIVO DE LOS COSTOS DEL PACIENTE CON CARCINOMA HEPATOCELULAR ENTRE REGIMENES CONTRIBUTIVO Y SUBSIDIADO

    Oct 1, 2019, 00:00

  • PMS20 DADOS DE MUNDO REAL DO USO DE IMUNOBIOLOGICOS DE PACIENTES COM ARTRITE REUMATOIDE

    Oct 1, 2019, 00:00

  • PDB13 ESTIMATION OF PATIENTS WITH INDICATION OF METABOLIC SURGERY IN THE PUBLIC AND PRIVATE SECTORS IN BRAZIL.

    Oct 1, 2019, 00:00

  • PMU6 ANALISIS DE COSTOS EN CUIDADO INTENSIVO Y CUIDADOS INTERMEDIOS DE UNA ASEGURADORA EN SALUD EN COLOMBIA

    Oct 1, 2019, 00:00

  • PIH13 CLINICAL BURDEN AND COSTS ASSOCIATED WITH PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN OLDER ADULTS IN CURITIBA, BRAZIL

    Oct 1, 2019, 00:00

  • PRS3 IDIOPATHIC PULMONARY FIBROSIS EXACERBATIONS : DIRECT COSTS OF MEDICAL RESOURCES

    Oct 1, 2019, 00:00

  • PSY2 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA PERUANA

    Oct 1, 2019, 00:00

  • PCN59 SUBJECT TRAINING IS NEEDED FOR KEY TERMINOLOGY IN ONCOLOGY CLINICAL TRIALS

    Oct 1, 2019, 00:00

  • PDG12 EXPERIENCIA INTERNACIONAL EN VALOR TERAPÉUTICO Y PRECIO BASADO EN VALOR. REVISIÓN RÁPIDA DE LA LITERATURA

    Oct 1, 2019, 00:00

  • PNS47 ANÁLISIS PARA LA IMPLEMENTACIÓN DE NUEVOS MODELOS DE ACCESO PARA EL SISTEMA NACIONAL DE SALUD DEL ECUADOR

    Oct 1, 2019, 00:00

  • PDG1 POLIMIXINA B: EXISTEM FATORES DE RISCO ASSOCIADOS À NEFROTOXICIDADE EM PACIENTES QUE UTILIZARAM ESTE MEDICAMENTO?

    Oct 1, 2019, 00:00

  • PCN30 REAL-WORLD DATA FOR COSTS RELATED TO CANCER MANAGEMENT IN BRAZIL: AN OVERVIEW OF THE LITERATURE

    Oct 1, 2019, 00:00

  • PIN23 EVALUACIÓN DE LAS PROPIEDADES PSICOMÉTRICAS DEL EQ-5D-5L EN PACIENTES CON VIH/SIDA EN COLOMBIA

    Oct 1, 2019, 00:00

  • HI4 ADHERENCE TO TREATMENT IS ASSOCIATED WITH GOOD CLINICAL RESULTS IN PATIENTS TREATED WITH BIOLOGICAL THERAPY IN A CENTER OF EXCELLENCE IN RHEUMATOID ARTHRITIS

    Oct 1, 2019, 00:00

  • PCN13 EVENTOS ADVERSOS ASOCIADOS A LOS TRATAMIENTOS DEL CARCINOMA UROTERIAL DE VEJIGA Y EL CARCINOMA DE CELULAS RENALES: ESTIMACION DE COSTOS DIRECTOS PARA ARGENTINA

    Oct 1, 2019, 00:00

  • PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION

    Oct 1, 2019, 00:00

  • MT4 ANALISIS DE IMPACTO PRESUPUESTARIO SOBRE LA INCORPORACION DEL COCIENTE SFLT-1/PLGF PARA PREDECIR EL RIESGO DE PREECLAMPSIA EN LA COBERTURA DE LAS OBRAS SOCIALES NACIONALES DE ARGENTINA

    Oct 1, 2019, 00:00

  • PND9 BUDGET IMPACT ANALYSIS OF CLADRIBINE COMPARED TO THE CURRENT COVERAGE SCHEME IN CHILE TO TREAT PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PDB9 ESTUDIO DE COSTOS DE LA HIPOGLICEMIA EN PACIENTES CON DIABETES MELLITUS TIPO 2 DESDE LA PERSPECTIVA DE SALUD PUBLICA DE CHILE

    Oct 1, 2019, 00:00

  • PUK4 FACTORES ASOCIADOS DE LA PROGRESION DE LA ENFERMEDAD RENAL CRONICA EN UN PROGRAMA DE INTERVENCION DEL RIESGO CARDIOVASCULAR DEL CARIBE COLOMBIANO

    Oct 1, 2019, 00:00

  • PDB2 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) LEVELS IN SELECTED LATIN AMERICAN COUNTRIES — HOW DOES IT MEASURE UP TO MAJOR GLUCOSE MONITORING GUIDELINES?

    Oct 1, 2019, 00:00

  • PIN14 INCREMENTAL PUBLIC HEALTH AND ECONOMIC IMPACT LINKED TO HIGHER VACCINE COVERAGE RATE IN A GENDER-NEUTRAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM IN BRAZIL

    Oct 1, 2019, 00:00

  • PNS33 HEALTH PROTECTION POLICIES FOR INTERNATIONAL MIGRANTS IN AN IRREGULAR SITUATION: THE CASE OF CHILE

    Oct 1, 2019, 00:00

  • PMD10 ESTUDIO MULTICÉNTRICO DE COSTOS DEL RECAMBIO PLASMÁTICO TERAPÉUTICO (RPT) CON LOS SISTEMAS DE FILTRACIÓN TRANSMEMBRANA Y DE CENTRIFUGACIÓN EN COLOMBIA

    Oct 1, 2019, 00:00

  • CL1 PATIENT ACTIVATION MEASURE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS IMPORTANCE REGARDING EMPOWERMENT

    Oct 1, 2019, 00:00

  • PCV14 IMPACTO DE LA INTERVENCION FARMACEUTICA (IF) EN LA NO ADHERENCIA A TRATAMIENTOS POR OMISION DE RETIRO DE MEDICAMENTOS FINANCIADOS

    Oct 1, 2019, 00:00

  • PMS4 MEDICATION PATTERNS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CHARACTERISTICS AND COSTS OF THERAPY

    Oct 1, 2019, 00:00

  • PIH11 ESTIMACION DE LA VARIACION DE COSTOS PRIVADOS E INSTITUCIONALES DE TRATAMIENTO DE LA DISMENORREA PRIMARIA EN MUJERES MEXICANAS.

    Oct 1, 2019, 00:00

  • PCN51 SYSTEMATIC REVIEW AND META-ANALYSIS OF 18F-FDG PET-CT FOR INITIAL STAGING OF PATIENTS WITH ESOPHAGEAL CANCER

    Oct 1, 2019, 00:00

  • PDB18 LA DIABETES Y SUS COMPLICACIONES EN LA ARGENTINA: EL CASO DEL PROGRAMA DE ATENCION INTEGRAL A LOS PACIENTES CON DIABETES MELLITUS EN LAS OBRAS SOCIALES NACIONALES

    Oct 1, 2019, 00:00

  • PCN21 ESTUDIO DE COSTO EFECTIVIDAD DE NIVOLUMAB PARA EL TRATAMIENTO DE SEGUNDA LINEA DEL CARCINOMA DE CELULAS RENALES METASTASICO DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO

    Oct 1, 2019, 00:00

  • PIN2 SISTEMA ELETRONICO INTEGRADO NO GERENCIAMENTO DO PROGRAMA STEWARDSHIP NUMA OPERADORA DE PLANOS DE SAUDE

    Oct 1, 2019, 00:00

  • PSU3 DETERMINACION DE CAMBIOS QUERATOMETRICOS POST QUIRURGICOS EN PACIENTES SOMETIDOS A PRK O LASIK MEDIANTE LASER EXCIMER VISX STAR S4IR

    Oct 1, 2019, 00:00

  • PGI6 CARGA DE ENFERMEDAD DIARREICA AGUDA ASOCIADA A MALA CALIDAD DEL AGUA, FALTA DE SANEAMIENTO E HIGIENE DE MANOS EN COLOMBIA, 2016

    Oct 1, 2019, 00:00

  • PRO10 EXPERIENCIA INTERNACIONAL EN EL USO DE ANÁLISIS DE DECISIÓN MULTICRITERIO (MCDA) PARA EVALUAR MEDICAMENTOS HUÉRFANOS: SCOPING REVIEW

    Oct 1, 2019, 00:00

  • PMU2 COSTOS DIRECTOS MÉDICOS EN COLOMBIA DESCRITOS EN EL ESTUDIO COMPASS: EVENTOS CARDIACOS AGUDOS MAYORES (MACE) Y EVENTOS ISQUEMICOS SEVEROS EN EXTREMIDADES (MALE)

    Oct 1, 2019, 00:00

  • PCV8 COST-EFFECTIVENESS ANALYSIS OF A RHEOLYTIC THROMBECTOMY SYSTEM FOR THE TREATMENT OF DEEP VEIN THROMBOSIS IN MEXICO

    Oct 1, 2019, 00:00

  • CE4 TRATAMIENTOS PARA LOS PACIENTES CON ESCLEROSIS MULTIPLE REMITENTE RECURRENTE CON ALTA ACTIVIDAD DE LA ENFERMEDAD: ANALISIS COSTO EFECTIVIDAD EN MEXICO

    Oct 1, 2019, 00:00

  • PCN48 HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN ONCOLOGY-RELATED TECHNOLOGIES IN BRAZIL: AN ASSESSMENT CONITEC'S RECOMMENDATIONS FROM 2012-2018

    Oct 1, 2019, 00:00

  • PCN38 SYSTEMATIC REVIEW OF RISK SHARING AGREEMENT IN ONCOLOGY: ADVANCES OR MORE OF THE SAME?

    Oct 1, 2019, 00:00

  • PCN47 PEG-ASPARAGINASE E L-ASPARAGINASE NATIVA DE ESCHERICHIA COLI NO TRATAMENTO FARMACOLOGICO DA LEUCEMIA LINFOBLASTICA AGUDA EM CRIANCAS E ADOLESCENTES: UMA REVISAO SISTEMATICA

    Oct 1, 2019, 00:00

  • PNS53 DESCRIPTION OF CLINICAL CHARACTERISTICS AND SELF REPORTED WILLINGNESS TO PAY FOR NEW TREATMENTS IN COLOMBIAN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS

    Oct 1, 2019, 00:00

  • PIH24 NUEVAMENTE: CALIDAD DE VIDA EN PERSONAS MAYORES DE UN SEGURO PRIVADO DE SALUD EN COLOMBIA

    Oct 1, 2019, 00:00

  • PMD11 REMOTE MONITORING COMPARED TO CONVENTIONAL FOLLOW-UP FOR PATIENTS WITH HEART FAILURE USING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2019, 00:00

  • PCN61 ANALISIS DE CORRELACION DE EQ5D 3L Y EORTC QLQ C30 EN POBLACION COLOMBIANA CON CANCER

    Oct 1, 2019, 00:00

  • PRO2 IMPACTO ORÇAMENTÁRIO DA IDURSULFASE NO TRATAMENTO DA MUCOPOLISSACARIDOSE TIPO 2

    Oct 1, 2019, 00:00

  • PBI9 MEDICATION USE AND REASONS FOR SWITCHING BIOLOGIC THERAPY IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: FINDINGS FROM A GLOBAL SURVEY

    Oct 1, 2019, 00:00

  • PMH3 ESKETAMINE SELF-PAY MODEL FOR TREATMENT RESISTANT DEPRESSION IN MEXICO

    Oct 1, 2019, 00:00

  • PCN46 ASSESSING THE QUALITY OF THE EVIDENCE OF NIVOLUMAB ACCORDING TO THE HTA REQUIREMENT IN ARGENTINA

    Oct 1, 2019, 00:00

  • PNS16 ANALYSIS OF THE DEMAND AND CONCESSIONS OF THE CONTINUED CASH BENEFIT FOR PERSONS WITH DISABILITIES UNDER 16 YEARS

    Oct 1, 2019, 00:00

  • CR1 LOS COSTOS INDIRECTOS DE LA MORTALIDAD MATERNA EN BRASIL: UN ESTUDIO DE COSTOS DE ENFERMEDADES

    Oct 1, 2019, 00:00

  • CM1 EFECTIVIDAD Y SEGURIDAD DE LA RESECCIÃN MUCOSA ENDOSCÃPICA FRENTE A LA DISECCIÃN SUBMUCOSA EN PACIENTES CON CÃNCER GÃSTRICO TEMPRANO: REVISIÃN SISTEMÃTICA CON METANÃLISIS

    Oct 1, 2019, 00:00

  • PDB15 SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR IN TYPE 2 DIABETES: PRESCRIPTION PATTERNS AND TREATMENT OUTCOMES IN ARGENTINA

    Oct 1, 2019, 00:00

  • HT3 BASE DE COSTOS UNITARIOS EN SALUD EN ARGENTINA: UNA FUENTE DE INFORMACIÓN CONTINUAMENTE ACTUALIZADA PARA EVALUACIONES ECONOMICAS Y ANALISIS DE IMPACTO PRESUPUESTARIO EN UN SISTEMA DE SALUD FRAGMENTADO

    Oct 1, 2019, 00:00

  • PMH11 BURDEN OF MENTAL ILLNESS IN THE PRESENCE OF CHRONIC DISEASES IN THE BRAZILIAN PRIVATE HEALTH

    Oct 1, 2019, 00:00

  • MT1 ANÁLISIS COSTO-EFECTIVIDAD DE UN SISTEMA DE TROMBECTOMÍA REOLÍTICA PARA EL TRATAMIENTO DE LA ISQUEMIA AGUDA DE MIEMBROS INFERIORES EN ADULTOS MEXICANOS

    Oct 1, 2019, 00:00

  • PIH1 COSTOS DIRECTOS FARMACÉUTICOS EN PACIENTES ANCIANOS CON POLIFARMACIA EXTREMA MAYOR DE 20 MEDICAMENTOS EN COLOMBIA

    Oct 1, 2019, 00:00

  • PDB16 AVALIAÇÃO DA EFICÁCIA E SEGURANÇA DO USO DO METIMAZOL EM COMPARAÇÁO A PROPILTIOURACILA PARA HIPERTIREOIDISMO

    Oct 1, 2019, 00:00

  • PSY3 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA COLOMBIANA

    Oct 1, 2019, 00:00

  • PCN32 PROSTATE CANCER MORTALITY TREND IN BRAZIL: A LINEAR REGRESSION ANALYSIS BETWEEN 1981 AND 2016

    Oct 1, 2019, 00:00

  • HT2 DISEÑO E IMPLEMENTACIÓN DE UN PROCESO DE INVOLUCRAMIENTO ACTIVO DE ACTORES RELEVANTES EN UNA AGENCIA DE EVALUACIÓN DE TECNOLOGÍAS SANITARIAS DE ARGENTINA

    Oct 1, 2019, 00:00

  • PRO6 BURDEN OF ILLNESS OF SPINAL MUSCULAR ATROPHY TYPE 1

    Oct 1, 2019, 00:00

  • PCN68 ADVANCED NON-SMALL CELL LUNG CANCER IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: RETROSPECTIVE COHORT STUDY

    Oct 1, 2019, 00:00

  • PMD2 ANALISIS DE IMPACTO PRESUPUESTARIO Y SANITARIO POR LA INCORPORACION DE UN DISPOSITIVO PORTATIL PARA EL CONTROL DE LOS PACIENTES ANTICOAGULADOS EN LA POBLACION DEL INSTITUTO NACIONAL DE SERVICIOS SOCIALES PARA JUBILADOS Y PENSIONADOS (P ...

    Oct 1, 2019, 00:00

  • PND3 COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST LINE THERAPY FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Oct 1, 2019, 00:00

  • PND7 COST-EFFECTIVENESS OF CLADRIBINE COMPARED TO NATALIZUMAB, OCRELIZUMAB AND ALEMTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN CHILE

    Oct 1, 2019, 00:00

  • PIH12 THE ECONOMIC IMPACT OF ENDOMETRIOSIS IN BRAZIL DUE TO PRODUCTIVITY LOSS

    Oct 1, 2019, 00:00

  • RE2 Definiendo “Valor” en Latinoamérica: Lo bueno, lo malo y lo feo

    Oct 1, 2019, 00:00

  • PNS32 COMPARATIVE ANALYSIS OF TENDER LEGISLATION IN BRAZIL AND MEXICO

    Oct 1, 2019, 00:00

  • PNS40 IMPACTO DE LA IMPLEMENTACIÓN DE UNA RED DE ATENCIÓN INTEGRADA EN SERVICIOS DE SALUD EN LA POBLACIÓN DEL NOROCCIDENTE COLOMBIANO

    Oct 1, 2019, 00:00

  • PND10 COMPARATIVE EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FURMURATE VERSUS OTHER DISEASE-MODIFYING THERAPIES IN PATIENTS WITH MULTIPLE SCLEROSIS: A DIRECT META-ANALYSIS OF REAL-WORLD EVIDENCE

    Oct 1, 2019, 00:00

  • CE1 COSTO-EFECTIVIDAD DE UNA INTERVENCIÃN ECO-SISTÃMICA PARA EL CONTROL DEL DENGUE EN GIRARDOT-COLOMBIA DESDE LA PERSPECTIVA DE LA SOCIEDAD

    Oct 1, 2019, 00:00

  • PDG7 EVALUACION ECONOMICA DE DEXAMETASONA IMPLANTE PARA EL TRATAMIENTO DE PACIENTES CON EDEMA MACULAR DIABETICO CON FALLA A LA TERAPIA ANTI-VEGF (RANIBIZUMAB O AFLIBERCEPT)

    Oct 1, 2019, 00:00

  • PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION

    Oct 1, 2019, 00:00

  • PDG15 SOLICITAÇÃO DE MEDICAMENTOS DO COMPONENTE ESPECIALIZADO NO ESTADO DE MINAS GERAIS: ESTRATÉGIA PARA REDUÇÃO DO TEMPO DE TRAMITAÇÃO E OTIMIZAÇÃO DESSE PROCESSO

    Oct 1, 2019, 00:00

  • PCN27 BUDGET IMPACT ANALYSIS OF MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA

    Oct 1, 2019, 00:00

  • PCN40 COSTS OF COMPREHENSIVE CARE OF HEPATOCELLULAR CARCINOMA IN A MODEL PUBLIC PROVIDER IN CHILE: IS IT POSSIBLE TO PROMOTE FINANCIAL COVERAGE?

    Oct 1, 2019, 00:00

  • PMS12 BENEFICIOS CLINICOS Y ECONOMICOS EN LA IMPLEMENTACION DE UNIDADES DE COORDINACION DE FRACTURAS (FLS) EN MEXICO

    Oct 1, 2019, 00:00

  • PIH14 BURDEN OF PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN OLDER ADULTS 60Y+ IN FIVE CAPITALS IN BRAZIL

    Oct 1, 2019, 00:00

  • PNS19 AN ANALYSIS OF CONTINUED CASH BENEFIT: PERSONS WITH DISABILITIES OVER 16 YEARS OLD

    Oct 1, 2019, 00:00

  • PRO5 ASSESSMENT OF COST-EFFECTIVENESS RESULTS FROM ICER ADVANCED THERAPIES MEDICINAL PRODUCTS REVIEWS

    Oct 1, 2019, 00:00

  • PUK6 AN EVALUATION OF THE BRAZILIAN POLICY FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE UNDER THE PERSPECTIVE OF THE PUBLIC HEALTH CARE SYSTEM: WAS IT EFFECTIVE?

    Oct 1, 2019, 00:00

  • PIN25 CALIDAD DE REVISIONES SISTEMATICAS CON EVALUACIONES DE COSTO-EFECTIVIDAD DE LA VACUNA CONTRA ROTAVIRUS DE PAISES LATINOAMERICANOS

    Oct 1, 2019, 00:00

  • PNS34 COMPARING REMUNERATION OF GENERAL PRACTITIONERS IN COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS

    Oct 1, 2019, 00:00

  • PIH23 SISTEMATIZACION DE EXPERIENCIAS EN EL DESARROLLO DE UNA ESTRATEGIA NO CONVENCIONAL PARA EDUCAR EN SALUD A GESTANTES DEL PROGRAMA SER MADRE-HIJO DE MUTUAL SER EPS.

    Oct 1, 2019, 00:00

  • PNS17 SELF-PERCEIVED DISCRIMINATION AMONG INTERNATIONAL MIGRANTS IN CHILE: RESULTS FROM A NATIONAL-BASED SURVEY (CASEN) 2017

    Oct 1, 2019, 00:00

  • PMU12 A NON-COMMUNICABLE DISEASES MULTI-CRITERIA ANALYSIS IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PIN16 ESTIMATED ANNUAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMMUNIZATION PROGRAM IN COLOMBIA (2011-2018)

    Oct 1, 2019, 00:00

  • Financial Disclosure Information

    Oct 1, 2019, 00:00

  • PDB8 IMPACTO ECONOMICO DE LA DIABETES MELLITUS TIPO II EN EL PERU EN EL ANHO 2017

    Oct 1, 2019, 00:00

  • PND2 TREATMENTS FOR HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS: COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

    Oct 1, 2019, 00:00

  • PNS38 INVESTIGATING QUALITY AND PERFORMANCE INDICATORS RELATED TO OUTPATIENT CARE USING THE DELPHI METHOD

    Oct 1, 2019, 00:00

  • PMU3 COSTOS DIRECTOS DE LA ATENCIÓN EN PACIENTES SUSCEPTIBLES DE CUIDADOS PALIATIVOS, EL CASO DE UNA ASEGURADORA EN SALUD EN COLOMBIA

    Oct 1, 2019, 00:00

  • PIH16 PATRONES DE USO DE ANTICONCEPTIVOS HORMONALES EN UNA POBLACIÓN DE COLOMBIA.

    Oct 1, 2019, 00:00

  • PCN35 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN BRAZIL

    Oct 1, 2019, 00:00

  • PND16 PREFERENCES OF PATIENTS FOR FEATURES OF INJECTABLE, ORAL, AND INFUSED DISEASE-MODIFYING TREATMENTS FOR RELAPSE-REMITTING MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PMD9 COST-EFFECTIVENESS ANALYSIS OF THREE-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY VERSUS TWO-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAM FOR THE EVALUATION OF PATIENTS WITH MITRAL REGURGITATION WITH INDICATION OF SURGICAL TREATMENT

    Oct 1, 2019, 00:00

  • PCN8 FINANCIAMIENTO DE MEDICAMENTOS ONCOLOGICOS MEDIANTE EL FONDO INTANGIBLE SOLIDARIO DE SALUD DEL PERU

    Oct 1, 2019, 00:00

  • PSY10 COST-EFFECTIVENESS ANALYSIS OF DRUG CHALLENGE TEST COMPARED TO SPECIFIC IGE DOSAGE FOR THE DIAGNOSIS OF PATIENTS WITH SUSPECT OF PENICILLIN ALLERGY

    Oct 1, 2019, 00:00

  • PIN7 ECONOMIC EVALUATION OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (GENVOYA®) AS A COMPLETE TREATMENT REGIMEN FOR HIV-1 INFECTION IN ADULTS WHO ARE ANTIRETROVIRAL THERAPY-NAÏVE IN MEXICO

    Oct 1, 2019, 00:00

  • CM3 REVIS SISTEMÃTICAS DOS MODELOS DE ORGANIZAÇÃO DE SISTEMAS PÚBLICOS DE SAÚDE PARA O CUIDADO DA OBESIDADE INFANTIL E SUA EFETIVIDADE NO MUNDO

    Oct 1, 2019, 00:00

  • PMS6 STANDARD COSTING OF DIRECT COSTS FOR PATIENTS WITH OSTEOARTHROSIS IN THE FIRST YEAR AFTER THE DISEASE WAS DIAGNOSED

    Oct 1, 2019, 00:00

  • PCN55 CALIDAD DE VIDA RELACIONADA CON LA SALUD Y DESENLACES PERCIBIDOS POR PACIENTES CON CANCER DE MAMA EN COLOMBIA

    Oct 1, 2019, 00:00

  • PBI8 O IMPACTO ECONOMICO DO PROCESSO DE VERTICALIZACAO NO USO DE IMUNOBIOLOGICOS INDICADOS PARA DOENCA DE CHRON EM UMA OPERADORA DE PLANOS DE SAUDE

    Oct 1, 2019, 00:00

  • PRS1 BUDGET IMPACT ANALYSIS OF UMECLIDINIUM VERSUS TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2019, 00:00

  • PNS56 ESTIMACIÓN DEL COSTO DOMICILIARIO EN LAS ALTAS TEMPRANAS PARA PACIENTES NO CRÓNICOS EN UNA RED INTEGRAL DE SALUD

    Oct 1, 2019, 00:00

  • CR4 ESTIMATION OF THE ECONOMIC AND HEALTH EFFECTS OF CHRONIC KIDNEY DISEASE IN CHILEAN POPULATION OLDER THAN 60 YEARS OLD

    Oct 1, 2019, 00:00

  • PAM3 COST MINIMIZATION BETWEEN READY TO USE OLIVE OIL-BASED PARENTERAL NUTRITION AND SUBROGATE COMPOUNDED PARENTERAL NUTRITION, ANALYSIS FROM A HIGH SPECIALITY REGIONAL MEXICAN HOSPITAL.

    Oct 1, 2019, 00:00

  • PIN12 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY COMPARED TO TUBERCULIN SKIN TEST FOR DETECTION OF LATENT TUBERCULOSIS IN RHEUMATOID ARTHRITIS PATIENTS USING IMMUNOBIOLOGICAL TREATMENTS

    Oct 1, 2019, 00:00

  • HT4 EXPERIENCIAS INTERNACIONALES ACERCA DE LOS CRITERIOS DE DECISIÓN USADOS EN LA PRIORIZACIÓN DE LAS TECNOLOGÍAS DE SALUD

    Oct 1, 2019, 00:00

  • PMH9 IMPACTO DE FACTORES SOCIOLOGICOS EN LA CALIDAD DE VIDA DE ADULTOS MAYORES INSTITUCIONALIZADOS CON DEPRESION: REVISION SISTEMATICA

    Oct 1, 2019, 00:00

  • PCN58 CANCER PATIENTS PREFER REPORTING SYMPTOMS IN DAILY ELECTRONIC DIARIES AT HOME

    Oct 1, 2019, 00:00

  • PMS9 EVALUACIÓN DE LA INCLUSIÓN DE DENOSUMAB EN EL PLAN DE BENEFICIOS DE SALUD EN COLOMBIA PARA EL TRATAMIENTO DE LA OSTEOPOROSIS: ANÁLISIS DE IMPACTO PRESUPUESTAL

    Oct 1, 2019, 00:00

  • PSU8 IS HIP ARTHROSCOPY COST EFFECTIVE IN TREATING FEMOROACETABULAR IMPINGEMENT? A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS

    Oct 1, 2019, 00:00

  • CV3 COST-EFFECTIVENESS OF A COMPREHENSIVE INTERVENTION FOR HYPERTENSION CONTROL IN LOW-INCOME SETTINGS IN ARGENTINA: A MARKOV MODEL

    Oct 1, 2019, 00:00

  • PCN60 EVALUATION OF EMOTIONAL, SOCIAL AND ACCESS NEEDS OF PATIENTS DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA IN COLOMBIA.

    Oct 1, 2019, 00:00

  • PGI9 PRIOR DIAGNOSIS OF GASTROINTESTINAL DISORDER DOES NOT INCREASE KNOWLEDGE OF GASTROINTESTINAL TERMINOLOGY OR ACCURACY OF SYMPTOM RATING

    Oct 1, 2019, 00:00

  • CV2 MODELO PREDICTIVO DEL RIESGO DE MUERTE EN PACIENTES DIABETICOS APLICADO EN UNA COMPAÑIA DE ASEGURAMIENTO EN SALUD DE COLOMBIA

    Oct 1, 2019, 00:00

  • PND17 THE BURDEN OF MIGRAINE IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PIN13 BUDGET IMPACT ANALISIS ( BIA) OF THE IMPLEMENTATION OF HIGH-RISK HPV GENOTYPING IN PATIENTS OF THE SOCIAL SECURITY OF ECUADOR (IESS) FOR PREVENTION OF CERVICAL CANCER

    Oct 1, 2019, 00:00

  • PCN67 ANALYSIS OF TREATMENT PATTERNS FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM IN DIFFERENT GEOGRAPHIC REGIONS OF BRAZIL

    Oct 1, 2019, 00:00

  • PNS41 VALUE BASED HEALTH CARE (CUIDADO BASADO EM VALOR) EN AMERICA LATINA: RESULTADOS PRELIMINARES DE UNA INVESTIGACION CON 40 HOSPITALES DE CINCO PAISES LATINOAMERICANOS

    Oct 1, 2019, 00:00

  • PUK3 COST CONSEQUENCE ANALYSIS OF A REMOTE PATIENT MONITORING PROGRAM TO IMPROVE CLINICAL PRACTICE OF AUTOMATED PERITONEAL DYALISIS IN BRAZIL

    Oct 1, 2019, 00:00

  • PAM1 RESULTADOS DE LA IMPLEMENTACION DEL MODELO DE SOPORTE NUTRICIONAL EN LOS NIVELES HOSPITALARIO Y DOMICILIARIO

    Oct 1, 2019, 00:00

  • PBI6 EVALUATION OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN COLOMBIA: A COST PER RESPONDER ANALYSIS (CPR)

    Oct 1, 2019, 00:00

  • PIN21 PROFILING PURCHASE VOLUMES AND EXPENDITURES WITH DIRECT-ACTING ANTIRETROVIRALS FOR HEPATITIS C BY THE BRAZILIAN MINISTRY OF HEALTH, 2015-2018

    Oct 1, 2019, 00:00

  • EP3 CARACTERIZACIÓN EPIDEMIOLÓGICA DE PACIENTES CON ARTRITIS REUMATOIDE ATENDIDOS EN SISTEMA GENERAL DE SEGURIDAD SOCIAL EN SALUD DE COLOMBIA.

    Oct 1, 2019, 00:00

  • CR2 IMPACTO ECONOMICO DE CANCER DE MAMA Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU

    Oct 1, 2019, 00:00

  • PCN57 PATIENTS WITH CANCER VIEW PHYSICAL SYMPTOMS AND IMPACT OF SYMPTOMS AS IMPORTANT INFORMATION TO PROVIDE HEALTHCARE PROVIDERS ON A DAILY BASIS

    Oct 1, 2019, 00:00

  • PCN66 IDENTIFICATION OF PATIENTS UNDERGOING TREATMENT OF LUNG CANCER IN THE BRAZILIAN NATIONAL HEALTH SYSTEM (SUS)

    Oct 1, 2019, 00:00

  • PIT4 SILICONE TAPES FOR PATIENTS WITH FRAGILE SKIN: A SYSTEMATIC REVIEW

    Oct 1, 2019, 00:00

  • PMU15 A MOBILE PHONE APP HEALTH CARE PROGRAM IN BRAZIL: SELF-REPORTS TO ASSESS DISEASE PREVALENCE

    Oct 1, 2019, 00:00

  • HI2 EVALUATION OF THE MEDICAL PROCEDURES ON AN ADMINISTRATIVE DATABASE TO IDENTIFY PATIENTS WITH SUSPECTED PRE-ECLAMPSIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • TP2 COSTS AND PRESCRIPTION PATTERN OF PATIENTS WITH PSORIATIC ARTHRITIS AND ITS ASSOCIATED COSTS

    Oct 1, 2019, 00:00

  • PCN19 ANÃLISE DO CUSTO-EFETIVIDADE DA RADIOTERAPIA COM INTENSIDADE MODULADA NO TRATAMENTO DO CÃNCER DE PRÃSTATA LOCALIZADO

    Oct 1, 2019, 00:00

  • HT1 TRANSFERIBILIDAD DE LAS EVALUACIONES ECONOMICAS PARA LA TOMA DE DECISIONES: UNA REVISION DE REVISIONES SISTEMATICAS

    Oct 1, 2019, 00:00

  • PMD5 ANALISIS DEL IMPACTO SANITARIO Y PRESUPUESTARIO POR LA INCORPORACION DEL TEST DE HPV CON GENOTIPIFICACION PARA EL TAMIZAJE PRIMARIO DE CANCER CERVICAL EN UNA POBLACION CERRADA DE UN HOSPITAL UNIVERSITARIO DE LA CIUDAD DE BUENOS AIRES

    Oct 1, 2019, 00:00

  • PCN26 IMPACTO DE LAS RECAÍDAS EN LOS PACIENTES COLOMBIANOS CON LINFOMA FOLICULAR

    Oct 1, 2019, 00:00

  • PND18 THE RESTORE REGISTRY: A RESOURCE FOR MEASURING AND IMPROVING SPINAL MUSCULAR ATROPHY OUTCOMES

    Oct 1, 2019, 00:00

  • PNS37 REVIEW OF QUALITY AND PERFORMANCE INDICATORS RELATED TO INPATIENT CARE IN SELF-FUNDED HEALTH PLANS

    Oct 1, 2019, 00:00

  • PNS57 REAL WORLD EVIDENCE LANDSCAPE IN LATIN AMERICA HEALTH CARE DECISION MAKING: EXPLORING UNDERSTANDING, ACCEPTABILITY AND USE

    Oct 1, 2019, 00:00

  • PCV10 EPIDEMIOLOGICAL STUDY DESIGN TO UNDERSTAND CARDIOVASCULAR RISK FACTORS AND TREATMENT IN GENERAL PRACTICE PATIENTS IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP

    Oct 1, 2019, 00:00

  • CN3 SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF COLORECTAL CANCER SCREENING STRATEGIES FOR THE EARLY DETECTION OF COLORECTAL CANCER IN THE GENERAL POPULATION

    Oct 1, 2019, 00:00

  • PNS6 VALUE-ASSESSMENT FRAMEWORKS: WE CANNOT ESCAPE THE ETHICAL DILEMMAS POSED BY THEIR USE

    Oct 1, 2019, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9 (current)
  • 10
  • »